SB1317 (TG-02)

SB1317 is a potent inhibitor of CDK2, JAK2, and FLT3 with IC50 of 13, 73, and 56 nM, respectively. SB1317 may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9).